Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Receivables (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Receivables for 15 consecutive years, with $16000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 97.35% to $16000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16000.0 through Dec 2025, down 97.35% year-over-year, with the annual reading at $16000.0 for FY2025, 97.35% down from the prior year.
  • Receivables hit $16000.0 in Q4 2025 for Perspective Therapeutics, down from $179000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.1 million in Q1 2022 to a low of $16000.0 in Q4 2025.
  • Historically, Receivables has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
  • Biggest YoY gain for Receivables was 58.45% in 2025; the steepest drop was 97.35% in 2025.
  • Year by year, Receivables stood at $1.6 million in 2021, then decreased by 17.12% to $1.4 million in 2022, then fell by 13.92% to $1.2 million in 2023, then crashed by 48.68% to $603000.0 in 2024, then crashed by 97.35% to $16000.0 in 2025.
  • Business Quant data shows Receivables for CATX at $16000.0 in Q4 2025, $179000.0 in Q3 2025, and $225000.0 in Q2 2025.